- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00811577
A Phase 2a Study to Evaluate the Safety and Efficacy of AZX100 in Trocar Sites of Arthroscopic Shoulder Surgery Patients
September 10, 2012 updated by: Capstone Therapeutics
A Phase 2a Double Blind, Placebo Within-Patient Controlled, Multi-Center Dose Ranging Study to Evaluate the Safety and Preliminary Efficacy of AZX100 Drug Product in Trocar Sites of Arthroscopic Shoulder Surgery Patients
The purpose of this study was to determine the safety of AZX100 Drug Product and to determine whether it was effective in preventing or reducing scars that were made from trocars following arthroscopic shoulder surgery.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
150
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Pasadena, California, United States, 91105
- Lotus Clinical Research, Inc.
-
-
Florida
-
Deland, Florida, United States, 32720
- Florida Research Associates
-
Orlando, Florida, United States, 32822
- Atlas Orthopedics & Sports Medicine
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
- Orthopaedics East, PA
-
-
Texas
-
Austin, Texas, United States, 78759
- Texas Orthopedics, Sports & Rehab Assoc.
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Scheduled for an arthroscopic shoulder surgery that will result in at least 3 trocar sites
- Healthy male or non-pregnant female 18-75 years old
- Non-diabetic
- Body Mass Index 18-35
- No clinically significant abnormal values on blood test
- Non-smoker for previous 6 months
Exclusion Criteria:
- History of acute or chronic disease
- Cancer within previous 5 years, except for removed skin cancer
- Hypersensitivity reaction
- Allergy to general anesthesia, lidocaine, or epinephrine
- Current skin disorder other than folliculitis or acne
- On therapy with steroids
- On therapy with a drug that affects collagen synthesis
- Positive for HIV or hepatitis
- Positive urine test for nicotine
- Positive blood test for anti-AZX100 antibodies
- Participated in another clinical study within 60 days before enrollment
- Gave blood within 7 days before dosing
- Gave plasma within 3 days before dosing
- Tattoo on the shoulder area
- Applied any prescribed or over the counter agents to the shoulder within 14 days before dosing, or intend to use any scar improving product
- Visited a tanning salon within 14 days before dosing
- History of drug addiction or excessive use of alcohol
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: PREVENTION
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: AZX100-placebo
Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive one low dose of AZX100 3 mg/linear cm, one high dose of AZX100 10 mg/linear cm, or placebo (saline).
|
Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery.
In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery.
The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery.
The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
|
PLACEBO_COMPARATOR: Placebo-only
Three trocar sites on each patient received one dose of placebo (saline).
|
Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery.
In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery.
The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Differences Among the 3 Dosage Groups in the Patient (PSAS) and Observer (OSAS) Scar Assessment Scale (POSAS) Scores
Time Frame: 12 months
|
Efficacy was based on the difference between mean POSAS scores of placebo and 3 mg AZX100, and placebo and 10 mg AZX100 12 months after shoulder surgery.
Three trocar sites were randomized on each patient to receive AZX100 3 mg or AZX100 10 mg or placebo at 9 days and 21 days after shoulder surgery.
PSAS results included patients' ratings on a scale of 1-10 (1 was normal skin or no complaints and 10 was the worst imaginable scar or the worst difference) for the following: Is the scar painful?
Is the scar itching?
Is the color of the scar different?
Is the scar more stiff?
Is the thickness of the scar different?
Is the scar irregular?
The possible minimum score was 6 and the maximum (worst) score was 60.
OSAS results included observers' ratings on a scale of 1-10 (1 was normal skin and 10 was the worst scar imaginable) for vascularization, pigmentation, thickness, relief, and pliability.
The possible minimum score was 5 and the possible maximum (worst) score was 50.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Between-group Mean Differences in Visual Analog Scale Scores Rated by Independent Blinded Raters Using 3D Photography
Time Frame: 12 months
|
Three trocar sites were randomized on each patient to receive AZX100 3 mg/cm or AZX100 10 mg/cm or saline placebo/cm at 9 days and 21 days after surgery.
Twelve months after surgery, images of the trocar sites were longitudinally evaluated and rated using a standard 100 mm Visual Analog Scale (VAS) by two blinded independent dermatologists, with 0 being normal skin and 100 being the worst scar imaginable.
Efficacy was based on the difference between VAS scores of placebo and 3 mg AZX100 and placebo and 10 mg AZX100 for each of the two raters separately.
Data from both raters was not combined.
|
12 months
|
Between-group Mean Differences in Objective Measures Via 3D Photography (Elevation, Length, Width)
Time Frame: 12 months
|
Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive AZX100 3 mg/cm or AZX100 10 mg/cm or placebo/cm at 9 days and 21 days following shoulder surgery.
3D digital photography of each trocar scar was used to calculate scar length, width, minimum elevation, and maximum elevation in millimeters (mm) at 12 months.
The minimum elevation value was calculated as the lowest point of the scar below the interpolated smooth skin surface.
This was always a negative number.
Negative values (closer to zero) were more desirable.
The maximum elevation value was the highest point of the scar above the interpolated smooth skin surface.
A smaller value was preferred.
|
12 months
|
Between-group Mean Differences in Objective Measures Via 3D Photography (Volume)
Time Frame: 12 months
|
Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive AZX100 3 mg/cm, or AZX100 10 mg/cm, or placebo/cm at 9 days and 21 days following shoulder surgery.
3D digital photography of each trocar scar was used to calculate positive volume, negative volume, and total volume in millimeters cubed (mm^3) at 12 months.
Positive volume included the scar volume that was calculated to be above the interpolated smooth skin surface.
A smaller value was preferred.
Negative volume included the volume of the scar calculated to be below the interpolated smooth skin surface.
It was always a negative number; negative values (closer to zero) were more desirable.
Total volume was calculated as the sum of positive volume and the absolute value of negative volume.
Smaller values were more desirable.
|
12 months
|
Histological Evaluation of Collagen
Time Frame: 12 months
|
Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive AZX100 3 mg/cm or AZX100 10 mg/cm or placebo/cm at 9 days and 21 days following shoulder surgery.
A skin punch biopsy was taken of each trocar site at 12 months.
The specimens were blindly scored in duplicate by a dermal pathologist for dermal collagen fiber density, maturity and orientation, where 0% was completely normal and 100% was completely abnormal.
|
12 months
|
Histological Evaluation of Number of Alpha Smooth Muscle Actin Cells
Time Frame: 12 months
|
Three trocar sites designated as anterior, lateral and posterior were randomized on each patient to receive AZX100 3 mg/cm or AZX100 10 mg/cm or placebo/cm at 9 days and 21 days following shoulder surgery.
A skin punch biopsy was taken of each trocar site at 12 months.
For exploratory purposes, the specimens were blindly scored in duplicate by a dermal pathologist for the estimated number of alpha-smooth muscle actin (α-SMA) positive cells per high powered field.
Values ranged from 0 to several hundred.
The number of α-SMA cells was assessed for exploratory purposes; therefore, at the time of this report, it was not known whether it was better to have a low or high α-SMA score.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2009
Primary Completion (ACTUAL)
December 1, 2010
Study Completion (ACTUAL)
December 1, 2010
Study Registration Dates
First Submitted
December 18, 2008
First Submitted That Met QC Criteria
December 18, 2008
First Posted (ESTIMATE)
December 19, 2008
Study Record Updates
Last Update Posted (ESTIMATE)
October 11, 2012
Last Update Submitted That Met QC Criteria
September 10, 2012
Last Verified
September 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- OL-ASCAR-03
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Scar Prevention
-
Lumenis Be Ltd.Terminated
-
PfizerCompletedScar PreventionUnited States
-
Thammasat University HospitalActive, not recruiting
-
PfizerCompleted
-
PfizerCompletedScar PreventionUnited States
-
Lemonex Inc.CompletedCicatrix | Scar PreventionKorea, Republic of
-
RXi Pharmaceuticals, Corp.CompletedCicatrix | Scar PreventionUnited States
-
RXi Pharmaceuticals, Corp.Completed
-
Capstone TherapeuticsCompletedScar Prevention | Scar ReductionUnited States
-
Hallym University Kangnam Sacred Heart HospitalRecruitingIntense Pulsed Light | Erbium-yttrium Aluminum Garnet Laser | Scar PreventionKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States